Effects of Alzheimer's disease transgenes on neurochemical expression in the mouse brain determined by 1H MRS in vitro

NMR in Biomedicine

Volumn 25, Issue 1, 2012, Pages 52-58

  Forster, D M ^a   James, M F ^b   Williams, S R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b The Nineveh Charitable Trust   (United Kingdom)

Author keywords

Alzheimer's disease; MRS; TASTPM mouse

Indexed keywords

AGE DEPENDENCE; ALZHEIMER'S DISEASE; AQUEOUS FRACTIONS; DISEASE PROGRESSION; DRUG DISCOVERY; ENERGY METABOLISM; GLYCEROPHOSPHOCHOLINE; HUMAN DISEASE; IN-VITRO; IN-VIVO; INTERNAL STANDARDS; METABOLITE CONCENTRATIONS; MOUSE BRAIN; MRS; MYO-INOSITOL; N-ACETYLASPARTATE; OSMOTIC STRESS; RESONANCE INTEGRAL; TASTPM MOUSE; TRANS-GENES; TRANSGENIC MODELS; TRANSGENICS; WILD TYPES;

AMINO ACIDS; BIOMARKERS; BRAIN MODELS; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; MAMMALS; METABOLISM; METABOLITES; METHANOL; NEURODEGENERATIVE DISEASES; SUGARS;

DISEASE CONTROL;

4 AMINOBUTYRIC ACID; ALANINE; AMYLOID PRECURSOR PROTEIN; ASPARTIC ACID; BIOLOGICAL MARKER; BRAIN PROTEIN; CHLOROFORM; CHOLINE; CREATINE; GLUTAMINE; INOSITOL; LACTIC ACID; METHANOL; N ACETYLASPARTIC ACID; PRESENILIN 1; SUCCINIC ACID; TAURINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; IN VITRO STUDY; MOUSE; NONHUMAN; OSMOTIC STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL NOISE RATIO; TRANSGENE;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN; CHOLINE; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; TRANSGENES;

ANIMALIA; MUS;

EID: 84855867025     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1712     Document Type: Article

References (37)

1. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 2005; 384: 23-28.
2. Bayer TA, Wirths O. Review on the APP/PS1KI mouse model: intraneuronal Abeta accumulation triggers axonopathy, neuron loss and working memory impairment. Genes Brain Behav. 2008; 7 Suppl 1: 6-11.
3. Bayer TA, Breyhan H, Duan K, Rettig J, Wirths O. Intraneuronal beta-amyloid is a major risk factor--novel evidence from the APP/PS1KI mouse model. Neurodegener. Dis. 2008; 5: 140-142.
4. Beacher F, Simmons A, Daly E et al. Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Arch. of gen. psych. 2005; 62: 1360-1365.
5. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361: 315-325.
6. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000; 1: 11-21.
7. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci. 1993; 15: 289-298.
8. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004; 1012: 60-65.
9. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 2002; 125: 2332-2341.
10. Drzezga A, Lautenschlager N, Siebner H et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging. 2003; 30: 1104-1113.
11. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997; 203: 829-836.
12. Ferguson KJ, MacLullich AM, Marshall I et al. Magnetic resonance spectroscopy and cognitive function in healthy elderly men. Brain 2002; 125: 2743-2749.
13. Frisoni GB, Fox NC, Jack CR, Jr., Scheltens P and Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010; 6: 67-77.
14. Garrard P, Schott JM, MacManus DG, Hodges JR, Fox NC, Waldman AD. Posterior cingulate neurometabolite profiles and clinical phenotype in frontotemporal dementia. Cogn. Behav. Neurol. 2006; 19: 185-189.
15. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
16. Howlett DR, Richardson JC, Austin A et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004; 1017: 130-136.
17. Howlett DR, Bowler K, Soden PE et al. Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histol. Histopathol. 2008; 23: 67-76.
18. Huang W, Alexander GE, Chang L et al. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 2001; 57: 626-632.
19. Jessen F, Block W, Traber F et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 2000; 55: 684-688.
20. Kantarci K, Smith GE, Ivnik RJ et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J. Int. Neuropsychol. Soc. 2002; 8: 934-942.
21. Kantarci K, Petersen RC, Boeve BF et al. 1H MR spectroscopy in common dementias. Neurology 2004; 63: 1393-1398.
22. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch. Neurol. 1996; 53: 678-860.
23. Lazeyras F, Charles HC, Tupler LA, Erickson R, Boyko OB, Krishnan K. Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. Psych. Res. 1998; 82: 95-106.
24. Le Belle JE, Harris NG, Williams SR, Bhakoo KK. A comparison of cell and tissue extraction techniques using high-resolution 1H-NMR spectroscopy. NMR Biomed. 2002; 15: 37-44.
25. Lien YH, Shapiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J. Clin. Invest. 1990; 85: 1427-1435.
26. Maheswaran S, Barjat H, Rueckert D et al. Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP x PS1 mice using MRI. Brain Res. 2009; 1270: 19-32.
27. Marjanska M, Curran GL, Wengenack TM et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U S A. 2005; 102: 11906-11910.
28. Moechars D, Dewachter I, Lorent K et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 1999; 274: 6483-6492.
29. Moreira PI, Siedlak SL, Wang X et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2007); 66: 525-532.
30. Rose SE, de Zubicaray GI, Wang D et al. A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn. Reson. Imaging. 1999; 17: 291-299.
31. Salek RM, Xia J, Innes A et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem. intnl. 2010; 56: 937-947.
32. Shonk TK, Moats RA, Gifford P et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65-72.
33. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem. 1992; 59: 55-61.
34. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 1993; 13: 981-989.
35. Valla J, Berndt JD, Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J. Neurosci. 2001; 21: 4923-4930.
36. von Kienlin M, Kunnecke B, Metzger F et al. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 2005; 18: 32-39.
37. Zhu X, Smith MA, Perry G, Aliev G. Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 2004; 19: 345-352.